Sio Gene Therapies, Inc. (SIOX) News
Filter SIOX News Items
SIOX News Results
|Loading, please wait...|
Latest SIOX News From Around the Web
Below are the latest news stories about Sio Gene Therapies Inc that investors may wish to consider to help them evaluate SIOX as an investment opportunity.
Insiders who bought stock earlier this year lose -US$183k as Sio Gene Therapies Inc. (NASDAQ:SIOX) drops to US$48m
The recent 10% drop in Sio Gene Therapies Inc.'s ( NASDAQ:SIOX ) stock could come as a blow to insiders who purchased...
In a report issued on February 11, Mani Foroohar from Leerink Partners maintained a Hold rating on Sio Gene Therapies (SIOX – Research Report), with a price target of $1.00. The company's shares closed last Tuesday at $0.69, close to its 52-week low of $0.66. According to TipRanks.com, Foroohar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -18.0% and a 38.3% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Recursion Pharmaceuticals, and 4D Molecular Therapeutics.
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Sio Gene Therapies (SIOX – Research Report) today and set a price target of $7.00. The company's shares closed last Thursday at $0.80, close to its 52-week low of $0.75. According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -14.3% and a 28.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Lineage Cell Therapeutics, and Actinium Pharmaceuticals. Sio Gene Therapies has an analyst consensus of Strong Buy, with a price target consensus of $5.00, representing a 525.0% upside.
Sio Gene Therapies press release (SIOX): Q3 GAAP EPS of -$0.35 misses by $0.12.Cash and cash equivalents of $81.9M as of December 31, 2021 Shares -2.50% PM.
Company prioritizing industry-leading clinical-stage programs, AXO-AAV-GM1 and AXO-AAV-GM2, the first potential disease-modifying therapies for GM1 gangliosidosis and Tay-Sachs/Sandhoff disease$81.9 million of cash and cash equivalents as of December 31, 2021, providing expected cash runway into calendar H2 2023 beyond the expected dates of major upcoming milestones for the AXO-AAV-GM1 and AXO-AAV-GM2 gene therapy programs NEW YORK and DURHAM, N.C., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Sio Gene The
NEW YORK and DURHAM, N.C., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today announced that it will present data in an oral platform presentation and two poster presentations at the 18th Annual WORLDSymposium™ 2022, to be held February 7-11, 2022. Presentations will include an update on the Phase 1/2 trial of AXO-AAV-GM1, the co
Rise and shine, trader!
Sio Gene Therapies Inc (NASDAQ: SIOX ) has decided to terminate its licensing agreement with Oxford Biomedica for AXO-Lenti-PD, its lentiviral gene therapy program for Parkinson''s disease. Due to several factors, the Company is deprioritizing its Parkinson''s disease program, including resource requirements, development timelines to reach meaningful value inflection, and a challenging market and regulatory environment. Sio Full story available on Benzinga.com
Biofrontera (BFRI) +14%. Synaptogenix (SNPX) +11%. Sio Gene Therapies (SIOX) -19%. Anavex Life Sciences (AVXL) -16%.
Sio Gene Therapies (SIOX) is trading ~10% lower in the post-market after announcing the resignation of its CEO, Dr. Pavan Cheruvu.Dr